L
Lori Luchtman-Jones
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 58
Citations - 1418
Lori Luchtman-Jones is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Sickle cell anemia & Acute chest syndrome. The author has an hindex of 19, co-authored 52 publications receiving 1170 citations. Previous affiliations of Lori Luchtman-Jones include Children's National Medical Center & St. Louis Children's Hospital.
Papers
More filters
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.
Journal ArticleDOI
Differences in the clinical and genotypic presentation of sickle cell disease around the world.
Santosh L. Saraf,Robert E. Molokie,Robert E. Molokie,Mehdi Nouraie,Craig Sable,Lori Luchtman-Jones,Gregory J. Ensing,Andrew D. Campbell,Sohail Rana,Xiao M. Niu,Roberto F. Machado,Mark T. Gladwin,Victor R. Gordeuk +12 more
TL;DR: Hb SS, absence of co-inheriting alpha-thalassemia, and low hemoglobin F levels tend to be associated with more hemolysis, lower hemoglobin oxygen saturations, greater proportions of elevated tricuspid regurgitant jet velocity and brain natriuretic peptide, and increased left ventricular mass index.
Journal ArticleDOI
Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia.
Deepika S. Darbari,Onyinye Onyekwere,Mehdi Nouraie,Caterina P. Minniti,Lori Luchtman-Jones,Sohail Rana,Sohail Rana,Craig Sable,Gregory J. Ensing,Niti Dham,Niti Dham,Andrew D. Campbell,Manuel Arteta,Mark T. Gladwin,Oswaldo Castro,James G. Taylor Vi,Gregory J. Kato,Victor R. Gordeuk +17 more
TL;DR: In a cohort of children with SCA, increasing age was associated with higher frequency of severe pain episodes as were α-thalassemia, iron overload, higher hemoglobin and lower lactate dehydrogenase concentration, and higher tricuspid regurgitation velocity.
Journal ArticleDOI
Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans
Harold Bae,Clinton T. Baldwin,Paola Sebastiani,Marilyn J. Telen,Allison E. Ashley-Koch,Melanie E. Garrett,W. Craig Hooper,Christopher J. Bean,Michael R. DeBaun,Dan E. Arking,Pallav Bhatnagar,James F. Casella,Jeffrey R. Keefer,Emily Barron-Casella,Victor R. Gordeuk,Gregory J. Kato,Caterina P. Minniti,James G. Taylor,Andrew D. Campbell,Lori Luchtman-Jones,Carolyn Hoppe,Mark T. Gladwin,Yingze Zhang,Martin H. Steinberg +23 more
TL;DR: Fetal hemoglobin protects against many but not all of the hematologic and clinical complications of sickle cell anemia, dependent on the ability of HbF to hinder deoxyHbS polymerization.
Journal ArticleDOI
Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.
Victor R. Gordeuk,Caterina P. Minniti,Mehdi Nouraie,Andrew D. Campbell,Sohail Rana,Lori Luchtman-Jones,Craig Sable,Niti Dham,Gregory J. Ensing,Josef T. Prchal,Gregory J. Kato,Mark T. Gladwin,Oswaldo Castro +12 more
TL;DR: Higher baseline hemolytic component and E/Etdi predicted elevated tricuspid regurgitation velocity at both baseline and follow up, and these elevations in turn predicted decline in six-minute-walk distance.